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Cerebral cavernous malformations (CCM) occur in two variants: sporadic and 
familial.  Mutations in three genes—CCM1, CCM2, and CCM3—play a role in both 
subtypes, with mouse models showing the development of multiple cavernous 
malformations in animals with loss of function in any of these three genes.  Identification 
of these genes has already allowed for improved screening of family members at risk for 
familial cavernous malformations, but deeper knowledge about the underlying 
physiology of these lesions could open up new avenues for treatment. 
A recent paper by Maddaluno et al. examines the role of endothelial-to-
mesenchymal transition (EndMT) in the development of CCMs (1).  EndMT is a set of 
irregularities in which endothelial tissues begin to exhibit mesenchymal tissue 
characteristics such as loss of cellular polarity, increased proliferative and migratory 
activity, and junctional disorganization.  Genetic abnormalities leading to EndMT have 
already been implicated in a number of conditions, and the authors sought to examine the 
role of loss-of-function mutations of CCM1 in CCM pathology. 
The authors bred mice with an endothelial-specific, tamoxifen-inducible CCM1 
loss-of-function mutation.  These mice subsequently developed multiple central nervous 
system vascular malformations that shared many characteristics with human 
CCMs.  Maddaluno et al. examined the endothelial cells of these lesions, which were 
found to have significantly elevated mesenchymal markers such as SLUG, inhibitor of 
DNA binding 1, and α-smooth muscle actin.  The abnormal cells also had significantly 
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To investigate why CCM1 loss-of-function induces EndMT, the authors began by 
examining the TGF-β pathway—a known inducer of EndMT.  They found that 
phosphorylation of SMAD1 and SMAD3—two mediators of TGF-β signaling—was 
dramatically increased in CCM1 knockout mice.  In addition, inhibition of the TGF-β 
pathway using LY-364947 (a TGF-β receptor and phosphorylated SMAD signaling 
inhibitor) inhibited EndMT, while further inhibition using a combination of LY-364947 
and SB-431542 (a second phosphorylated pSMAD inhibitor) actually decreased number 
and size of vascular lesions (Figure 1).  These data, combined with the observation that 
animals with CCM1 loss of function did not have inherently higher TGF-β levels or more 
TGF-β receptors, suggested that an increased sensitivity to TGF-β is one of the effects of 
CCM1 mutation.  
Gene products involved in the TGF-β signaling pathway were tested to identify 
what could mediate this increased sensitivity to TGF-β.  The factor that appeared most 
significantly elevated in abnormal endothelial cells was bone morphogenic protein 6 
(BMP6), a protein that facilitates SMAD phosphorylation.  Supporting the role of BMP6 
in EndMT, Maddaluno et al. found that EndMT markers were significantly decreased in 
cells where BMP signaling was inhibited using the BMP inhibitor DMH1 and in animals 
who had BMP loss-of-function mutations.  Previous studies had shown that CCM1 acts 
as a Notch signaling pathway activator, one of the downstream effects of which is 
inhibition of BMP6 expression.  The authors therefore concluded that CCM1 loss of 
function leads to inhibition of Notch signaling, which allows for increased BMP6 activity 
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Although this study was conducted using a mouse model, Maddaluno et al. 
observed that lesions obtained from human patients with CCM1 and CCM2 mutations 
demonstrated similar pSMAD3 upregulation, increased N-cadherin expressivity, and VE-
cadherin disorganization.  They believe that further elucidation of mechanisms of EndMT 
in cavernous malformations could lead to future therapeutic targets and a better 
understanding of the development and growth of CCMs. Such innovations could greatly 
enhance our ability to manage CCMs, especially those in high-risk surgical locations or 
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Figure 1: TGF-β signaling inhibition reduces number and size of lesions and vessel 
leakage.  a, Wild-type, iCCM1 vehicle-treated and LY-364947/SB-431542-treated mouse 
brains after dissection (left) and quantification of number and size of lesions (right) (n = 4 
in each group from three different litters). b, Whole brains photographed after fluorescent 
cadaverine injection (left) and quantification of the recovered fluorescence (right). Data 
are mean ± .d. c, Confocal microscopy of astrocytes (GFAP staining) in CCM lesions 
(dotted areas) of iCCM1 vehicle- and LY-364947/SB-431542-treated animals. 
Arrowheads denote normal astrocyte coverage in a LY-364947/SB-431542-treated mouse 
(red magnification). Arrows denote astrocyte detachment from a vascular lesion of a 
vehicle treated mouse (yellow magnification). Data are mean ± s.d. Scale bars, 500 μm 
(a, b); 60 μm (c); 20 μm (magnifications in c). *P < 0.05; **P < 0.01; ***P < 0.001. 
(Figure reproduced with permission from Maddaluno L, Rudini N, Cuttano R, Bravi L, 
Giampietro C, Corada M, Ferrarini L, Orsenigo F, Papa E, Boulday G, Tournier-Lasserve 
E, Chapon F, Richichi C, Retta SF, Lampugnani MG, Dejana E: EndMT contributes to 
the onset and progression of cerebral cavernous malformations. Nature advance online 
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